A novel infrared spectroscopic approach to study the interaction of amyloid-B with cell-penetrating peptides—a possible new class of drugs to combat Alzheimer's disease

Alzheimer's disease is the most common type of neurodegenerative disease where amyloid-β (Aβ) peptide aggregates to amyloid fibers that accumulate as plaques in the human brain. Recent in vitro results demonstrated that Aβ aggregation can be inhibited by certain cell-penetrating peptides (CPPs) containing a signal sequence NCAM1 for secretion and a short sequence from an amyloidogenic polypeptide (PrP or Aβ).